Forecast

There is no analyst data available for this company.

News Go to news feed

Revenio Group share plunges after margin pressure and high debt

Revenio Group reported significant reported sales growth in Q2 following the acquisition of Visionix, while gross margins fell sharply and the organic core business stagnated. Net sales rose to EUR 39.6m, gross margin fell to 64.7%, and net debt increased to EUR 238m (leverage 5.3x adjusted EBITDA). Management reports faster integration and already secured synergies of EUR 5m, but plans a mandatory capital increase of over EUR 80m and expects currency-adjusted revenue of EUR 190–205m in 2026. The stock fell sharply in pre-market trading as investors prioritized profitability pressure and balance-sheet risks over the revenue increase. » More on de.investing.com
Revenio increases revenue in Q3 2025 by 8.1% and improves EBIT

Revenio reports net revenue of €25.9m for Q3 2025 (+8.1%, slightly above analysts' expectations) and an operating profit (EBIT) of €6.0m (+9.1%). Earnings per share were €0.173; for the nine-month period net revenue rose to €78.5m (+7.5%) and EBIT to €18.7m (+17.8%). The balance sheet remains strong with an equity ratio of 79.6% and net gearing of -2.8%. Revenio launches the iCare ALTIUS data platform, sees growth potential in software and AI offerings, and confirms 2025 constant-currency revenue growth guidance of 6–15%, while noting currency headwinds in the Asia-Pacific region and about €2m of FDA-related costs. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2025, Revenio Group has already paid €0.40 in dividends. The last payout was in April 2025.

Financials

In the last quarter, Revenio Group had revenue of €39.3m and net profit of €600k

(EUR)	June 2026	YoY
Revenue	39.3m	48.30%
Gross profit	13.4m	15.52%
Net profit	600k	80.65%
EBITDA	2.4m	66.67%

Fundamentals

Metric	Value
Market capitalization	€357.87m
Number of shares	26.71m
52-week high/low	€41.32 - €13.36
Dividends	No
Beta	0.85
P/E ratio	26.87
PEG ratio	-0.93
P/B ratio	2.65
P/S ratio	3.11

Company profile

Die Revenio Group Oyj, ein Unternehmen der Gesundheitstechnologie, entwickelt, produziert und vertreibt ophthalmologische Diagnostika und Geräte zur Erkennung von Glaukom, Makuladegeneration, diabetischer Retinopathie und Katarakt in Finnland, im übrigen Europa und international. Das Unternehmen bietet iCare IC100- und IC200-Tonometer, iCare HOME, ein Gerät zur Selbstmessung des Augendrucks, Bildgebungsgeräte, darunter iCare EIDON AF, ein Gerät mit konfokaler Netzhautbildgebung, DRSplus, ein Gerät zur Erkennung von diabetischer Retinopathie, iCare MAIA, ein Mikroperimeter zur Messung des Gesichtsfelds, und iCare COMPASS, das Fundusperimetrie mit konfokalen Echtfarben-Netzhautbildern bietet. Darüber hinaus bietet das Unternehmen Oculo an, eine Softwareplattform für die Augenheilkunde, die klinische Kommunikation, Telemedizin, Fernüberwachung von Patienten und Datenanalysefunktionen kombiniert. Die Revenio Group Oyj wurde im Jahr 2001 gegründet und hat ihren Sitz in Vantaa, Finnland.